对局部肌层浸润性膀胱癌初始全身治疗达临床完全缓解患者行保留膀胱策略肿瘤学结局的系统综述
本系统综述纳入1990至2021年发表的23项非比较性前瞻或回顾性研究,评估局部肌层浸润性膀胱癌(MIBC)患者对初始全身治疗达临床完全缓解(cCR)后接受监测或放疗的肿瘤学结局。监测组16项研究(n=610)、放疗组7项研究(n=175),仅有低级别证据支持保留膀胱策略(BSS)在经选择患者中的有效性,作者提出需进一步前瞻性比较研究。
要点
- 监测组平均膀胱复发率43%(0-71%),其中非肌层浸润性膀胱癌(NMIBC)占65%、MIBC占35%。
- 监测组平均保留膀胱率73%(49-100%),平均转移复发率9%(0-27%),5年总生存率64%-89%。
- 放疗组平均膀胱复发率15%(0-29%),平均保留膀胱率74%(71-100%),平均转移复发率17%(0-22%),4年总生存率79%。
核心结论
- 本系统综述显示,仅有低级别证据支持BSS在局部MIBC初始全身治疗达cCR的经选择患者中的有效性。
- 这些初步发现突出表明,需要进一步的前瞻性比较研究来证明其疗效。
研究设计与样本
- 采用系统综述方法,按PRISMA指南检索Medline、Embase和Cochrane数据库,纳入1990至2021年发表的23项非比较性前瞻或回顾性研究。
主要发现
- 监测组16项研究(n=610),中位随访10至120个月,平均膀胱复发率43%(0-71%),其中NMIBC占65%、MIBC占35%,平均保留膀胱率73%(49-100%),平均转移复发率9%(0-27%),5年总生存率64%-89%。
- 放疗组7项研究(n=175),中位随访12至60个月,平均膀胱复发率15%(0-29%),其中NMIBC占24%、MIBC占43%、未明确类型占33%,平均保留膀胱率74%(71-100%),平均转移复发率17%(0-22%),4年总生存率79%。
临床怎么用
- 原文结论未据此给出推荐,仅指出低级别证据支持BSS在经选择患者中的有效性,并需要进一步前瞻性比较研究来证明其疗效。
局限性
- 原文结论指出仅有低级别证据支持BSS的有效性。
- 原文结论指出这些为初步发现,需要进一步前瞻性比较研究来证明其疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Bladder-sparing strategies (BSSs) have been proposed for the treatment of muscle-invasive bladder cancer (MIBC) patients achieving clinical complete response (cCR) to initial systemic treatment to avoid toxicity related to radical cystectomy. OBJECTIVE: To systematically review the current literature evaluating oncological outcomes of BSSs in patients achieving cCR to initial systemic treatment for localized MIBC. EVIDENCE ACQUISITION: A computerized bibliographic search of the Medline, Embase, and Cochrane databases was performed for all studies reporting oncological outcomes of MIBC patients undergoing either surveillance or radiation therapy after achieving cCR to initial systemic treatment. Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we identified 23 noncomparative prospective or retrospective studies published between 1990 and 2021. The mean bladder and metastatic recurrence rates (range) as well as the mean bladder preservation rate (BPR; range) were calculated, and overall survival (OS) was extracted from included reports. EVIDENCE SYNTHESIS: Overall, 16 and seven studies evaluated surveillance (n = 610) and radiation therapy (n = 175) in MIBC patients achieving cCR to initial systemic treatment, respectively. With regard to surveillance, the median follow-up ranged from 10 to 120 mo, with a mean bladder recurrence rate of 43% (0-71%), including 65% of non-muscle-invasive bladder cancer (NMIBC) and 35% of MIBC recurrences. The mean BPR was 73% (49-100%). The mean metastatic recurrence rate was 9% (0-27%), while 5-yr OS rates ranged from 64% to 89%. With regard to radiation therapy, the median follow-up ranged from 12 to 60 mo, with a mean bladder recurrence rate of 15% (0-29%), including 24% of NMIBC, 43% of MIBC, and 33% of unspecified recurrences. The mean BPR was 74% (71-100%). The mean metastatic recurrence rate was 17% (0-22%), while the 4-yr OS rate was 79%. CONCLUSIONS: Our systematic review showed that only low-level evidence supports the effectiveness of BSSs in selected patients achieving cCR to initial systemic treatment for localized MIBC. These preliminary findings highlight the need for further prospective comparative research to demonstrate its efficacy. PATIENT SUMMARY: We reviewed studies evaluating bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized muscle-invasive bladder cancer. Based on low-level evidence, we observed that selected patients could benefit from surveillance or radiation therapy in this setting, but prospective comparative research is requested to confirm their efficacy.
引用
- Grobet-Jeandin E, Lenfant L, Mir C, et al. A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023. PMID: 36906510. doi:10.1016/j.euo.2023.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。